Skip to content
My WebMD Sign In, Sign Up
Font Size

Genetics of Prostate Cancer (PDQ®): Genetics - Health Professional Information [NCI] - Genes With Potential Clinical Relevance in Prostate Cancer Risk

Table 3. Case-Control Studies in Ashkenazi Jewish Populations ofBRCA1andBRCA2and Prostate Cancer Risk continued...

These studies support the hypothesis that prostate cancer occurs excessively among carriers of AJ founder mutations and suggest that the risk may be greater among men with the BRCA2 founder mutation (6174delT) than among those with one of the BRCA1 founder mutations (185delAG; 5382insC). The magnitude of the BRCA2-associated risks differ somewhat, undoubtedly because of interstudy differences related to participant ascertainment, calendar time differences in diagnosis, and analytic methods. Some data suggest that BRCA-related prostate cancer has a significantly worse prognosis than prostate cancer that occurs among noncarriers.[16]

Other populations

The association between prostate cancer and mutations in BRCA1 and BRCA2 has also been studied in other populations.

Three Polish BRCA1 founder mutations (C16G, 4153delA, and 5382insC) were studied in 1,793 Polish prostate cancer cases and 4,570 controls. Overall, the prevalence of the three mutations combined was identical in cases and controls. However, the most common mutation, 5382insC, occurred in 0.06% of cases versus 0.37% of controls, suggesting that this specific variant is not likely to be associated with increased prostate cancer risk. Furthermore, the presence of either of the other two mutations (C16G and 4153delA) was associated with a 3.6-fold increase in prostate cancer risk (P = .045) and an even greater risk (OR, 12; P = .0004) of familial prostate cancer. These data suggest that prostate cancer risk in BRCA1 mutation carriers varies with the location of the mutation (i.e., there is a correlation between genotype and phenotype).[17] This observation might explain some of the inconsistencies encountered in prior studies of this association, since populations may have varied relative to the proportion of persons with specific pathogenic BRCA1 mutations.

Several case series have also explored the role of BRCA1 and BRCA2 mutations and prostate cancer risk.

1|2|3|4|5|6|7

WebMD Public Information from the National Cancer Institute

Last Updated: February 25, 2014
This information is not intended to replace the advice of a doctor. Healthwise disclaims any liability for the decisions you make based on this information.
Next Article:

Today on WebMD

man with doctor
Symptoms, risks, treatments
man coughing
Men shouldn’t ignore
 
prostate cancer cells
What does this diagnosis mean?
doctor and male patient
Is it worth it?
 
cancer fighting foods
SLIDESHOW
15 Cancer Symptoms Men Ignore
FEATURE
 
Prostate Enlarged
VIDEO
Picture Of The Prostate
ANATOMY
 
Prostate Cancer Quiz
QUIZ
screening tests for men
SLIDESHOW
 
Prostate Cancer Symptoms
VIDEO
Vitamin D
SLIDESHOW